Induction of interleukin-1β, tumour necrosis factor-α and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 5, 2005, Pages 713-720

  Falk, Rama ^a   Hacham, Moshe ^a   Nyska, Abraham ^b   Foley, Julie F ^b   Domb, Abraham J ^c   Polacheck, Itzhack ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

AMB formulations; AMB toxicity; Antifungals; Cytokines

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ARABINOGALACTAN; INTERLEUKIN 1BETA; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA; AMPHOTERICIN B; AMPHOTERICIN B-DEOXYCHOLATE; ANTIFUNGAL AGENT; CYTOKINE; DEOXYCHOLIC ACID; GALACTAN; INTERLEUKIN 1;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY FLUID; BRAIN TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY TUBULE CELL; LIVER PARENCHYMA; LUNG PARENCHYMA; MALE; MOUSE; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; SPLEEN; TISSUE INJURY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; APOPTOSIS; CYTOKINES; DEOXYCHOLIC ACID; DRUG COMBINATIONS; GALACTANS; INTERLEUKIN-1; KIDNEY; MALE; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18844446115     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki090     Document Type: Article

References (57)

1. Odds, F. C., Brown, A. J. & Gow, N. A. (2003). Antifungal agents: mechanisms of action. Trends in Microbiology 11, 272-9.
2. Dupont, B. (2002). Overview of the lipid formulations of amphotericin B. Journal of Antimicrobial Chemotherapy 49, Suppl. 1, 31-6.
3. Garber, G. (2001). An overview of fungal infections. Drugs 61, Suppl. 1, 1-12.
4. Polak, A. (2003). Antifungal therapy - state of the art at the beginning of the 21st century. Progress in Drug Research, Special Issue 59-190.
5. Segal, B. H., Bow, E. J. & Menichetti, F. (2002). Fungal infections in nontransplant patients with hematologic malignancies. Infectious Disease Clinics of North America 16, 935-64.
6. Paya, C. V. (2002). Prevention of fungal infection in transplantation. Transplant Infectious Disease 4, Suppl. 3, 46-51.
7. Marty, F. & Mylonakis, E. (2002). Antifungal use in HIV infection. Expert Opinion on Pharmacotherapy 3, 91-102.
8. Fung, J. J. (2002). Fungal infection in liver transplantation. Transplant Infectious Disease 3, Suppl. 4, 18-23.
9. Walsh, T. J., Finberg, R. W., Arndt, C. et al. (1999). Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New England Journal of Medicine 340, 764-71.
10. Deray, G. (2002). Amphotericin B nephrotoxicity. Journal of Antimicrobial Chemotherapy 49, Suppl. 1, 37-41.
11. Fanos, V. & Cataldi, L. (2000). Amphotericin B-induced nephrotoxicity: a review. Journal of Chemotherapy 12, 463-70.
12. Hehlgans, T. & Mannel, D. N. (2002). The TNF-TNF receptor system. Biological Chemistry 383, 1581-5.
13. Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. Blood 87, 2095-147.
14. Eizirik, D. L. & Mandrup-Poulsen, T. (2001). A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44, 2115-33.
15. Rogers, P. D., Barker, K. S., Herring, V. et al. (2003). Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1. Journal of Antimicrobial Chemotherapy 51, 405-8.
16. Sau, K., Mambula, S. S., Latz, E. et al. (2003). The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. Journal of Biological Chemistry 278, 37561-8.
17. Shadkchan, Y., Keisari, Y. & Segal, E. (2004). Cytokines in mice treated with amphotericin B-intralipid. Medical Mycology 42, 123-8.
18. Arning, M., Kliche, K. O., Heer-Sonderhoff, A. H. et al. (1995). Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38, 459-65.
19. Varlam, D. E., Siddiq, M. M., Parton, L. A. et al. (2001). Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrobial Agents and Chemotherapy 45, 679-85.
20. Duncan, R., Gac-Breton, S., Keane, R. et al. (2001). Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. Journal of Controlled Release 74, 135-46.
21. Domb, A. J., Linden, G., Polacheck, I. et al. (1996). Nystatin-dextran conjugates: synthesis and characterization. Journal of Polymer Science Part A: Polymer Chemistry 34, 1229-36.
22. Ehrenfreund-Kleinman, T., Azzam, T., Falk, R. et al. (2002). Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Biomaterials 23, 1327-35.
23. Falk, R., Domb, A. J. & Polacheck, I. (1999). A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrobial Agents and Chemotherapy 43, 1975-81.
24. Falk, R., Grunwald, J., Hoffman, A. et al. (2004). Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Antimicrobial Agents and Chemotherapy 48, 3606-9.
25. Golenser, J., Frankenburg, S., Ehrenfreund, T. et al. (1999). Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrobial Agents and Chemotherapy 43, 2209-14.
26. 2 shift on autoimmune and anti-inflammatory processes. Cytokine 19, 85-93.
27. Ledeboer, A., Binnekade, R., Breve, J. J. et al. (2002). Site-specific modulation of LPS-induced fever and interleukin-1β expression in rats by interleukin-10. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 282, R1762-72.
28. Crissman, J. W., Goodman, D. G., Hildebrandt, P. K. et al. (2004). Best practices guideline: toxicologic histopathology. Toxicologic Pathology 32, 126-31.
29. Gavrieli, Y., Sherman, Y. & Ben-Sasson, S. A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology 119, 493-501.
30. Boucher, H. W., Groll, A. H., Chiou, C. C. et al. (2004). Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64, 1997-2020.
31. --cotransport blocker bumetanide. Life Sciences 66, PL319-24.
32. Brauner, A., Soderhall, M., Jacobson, S. H. et al. (2001). Escherichia coli-induced expression of IL-1α, IL-1β, IL-6 and IL-8 in normal human renal tubular epithelial cells. Clinical and Experimental Immunology 124, 423-8.
33. Macica, C. M., Escalante, B. A., Conners, M. S. et al. (1994). TNF production by the medullary thick ascending limb of Henle's loop. Kidney International 46, 113-21.
34. Donnahoo, K. K., Meng, X., Ao, L. et al. (2001). Differential cellular immunolocalization of renal tumour necrosis factor-α production during ischaemia versus endotoxaemia. Immunology 102, 53-8.
35. Meldrum, K. K., Meldrum, D. R., Hile, K. L. et al. (2001). p38 MAPK mediates renal tubular cell TNF-α production and TNF-α-dependent apoptosis during simulated ischemia. American Journal of Physiology - Cell Physiology 281, C563-70.
36. Ramesh, G. & Reeves, W. B. (2002). TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. Journal of Clinical Investigation 110, 835-42.
37. Ortiz, A., Lorz, C., Catalan, M. P. et al. (2000). Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney International 57, 969-81.
38. Jo, S. K., Cha, D. R., Cho, W. Y. et al. (2002). Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells. Nephron 91, 406-15.
39. Escalante, B. A., Ferreri, N. R., Dunn, C. E. et al. (1994). Cytokines affect ion transport in primary cultured thick ascending limb of Henle's loop cells. American Journal of Physiology 266, C1568-76.
40. Weingartner, M., Siegmund, D., Schlecht, U. et al. (2002). Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis. Journal of Biological Chemistry 277, 34853-9.
41. Aggarwal, B. B. (2003). Signalling pathways of the TNF super-family: a double-edged sword. Nature Reviews Immunology 3, 745-56.
42. Maisey, K., Nardocci, G., Imarai, M. et al. (2003). Expression of proinflammatory cytokines and receptors by human fallopian tubes in organ culture following challenge with Neisseria gonorrhoeae. Infection and Immunity 71, 527-32.
43. Bellone, G., Turletti, A., Artusio, E. et al. (1999). Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreafic carcinoma patients. American Journal of Pathology 155, 537-47.
44. Giroir, B. P., Johnson, J. H., Brown, T. et al. (1992). The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. Journal of Clinical Investigation 90, 693-8.
45. Cunningham, P. N., Dyanov, H. M., Park, P. et al. (2002). Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. Journal of Immunology 168, 5817-23.
46. Al-Lamki, R. S., Wang, J., Skepper, J. N. et al. (2001). Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Laboratory Investigation 81, 1503-15.
47. Rothwell, N. J. & Luheshi, G. N. (2000). Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends in Neurosciences 23, 618-25.
48. Tatsuta, T., Cheng, J. & Mountz, J. D. (1996). Intracellular IL-1β is an inhibitor of Fas-mediated apoptosis. Journal of Immunology 157, 3949-57.
49. Vertut-Doi, A., Ohnishi, S. I. & Bolard, J. (1994). The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrobial Agents and Chemotherapy 38, 2373-9.
50. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 512-31.
51. Ramaswamy, M., Peteherych, K. D., Kennedy, A. L. et al. (2001). Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrobial Agents and Chemotherapy 45, 1184-91.
52. Hartsel, S. C., Baas, B., Bauer, E. et al. (2001). Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-α. Journal of Pharmaceutical Sciences 90, 124-33.
53. Begum, N. A., Ishii, K., Kurita-Taniguchi, M. et al. (2004). Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infection and Immunity 72, 937-48.
54. Camacho, M., Gerboles, E., Soler, M. et al. (2004). Modification of prostanoid secretion in endothelial cells by amphotericin B acting synergistically with interleukin-1β: possible explanation of proinflammatory effects. Journal of Infectious Diseases 190, 1026-32.
55. Suschek, C. V., Bonmann, E., Kapsokefalou, A. et al. (2002). Revisiting an old antimicrobial drug: amphotericin B induces interleukin-1-converting enzyme as the main factor for inducible nitric-oxide synthase expression in activated endothelia. Molecular Pharmacology 62, 936-46.
56. Cutaia, M., Bullard, S. R., Rudio, K. et al. (1993). Characteristics of amphotericin B-induced endothelial cell injury. Journal of Laboratory and Clinical Medicine 121, 244-56.
57. Binet, A. & Bolard, J. (1988). Recovery of hepatocytes from attack by the pore former amphotericin B. Biochemical Journal 253, 435-40.